The Medicines Co. Takes On The Gram-Negative Competition
This article was originally published in Pharmaceutical Approvals Monthly
Hospital-focused specialty firm expects novel beta lactamase inhibitor in Carbavance will provide a crucial advantage in attacking developing gram-negative infections. TMC also is re-launching tetracycline antibiotic Minocin for gram-negative infections, while developing a follow-on formulation that should offer easier administration.
You may also be interested in...
With Reckitt's OTC sales falling 3% in 2020, the firm has committed to doubling its R&D spend in search of breakthrough product innovations.
Taiwan’s JHL Biotech has rebranded itself as Eden Biologics at the same time as it has announced progress on clinical trials for its denosumab biosimilar candidate.
Starpharma's COVID-busting Viraleze antiviral nasal spray will soon be available across Europe, included the UK. But will it fall foul of local evidence requirements, for example in France, where the country's medicines agency has halted the sale of Pharma & Beauty (P&B) Group's COV-Defense spray until its efficacy against COVID has been confirmed by human-based studies?